The jeans at the back of the closet
They still fit everywhere except one place.
That was always the strange part, the part you never quite said out loud. Your arms are the same. Your legs are the same. The boots still zip, the sleeves still button at the wrist, your rings still turn on your fingers the way they always have. It is the waistband. Only ever the waistband.
So you did the reasonable thing. You bought the next size, and when that one stopped closing you bought the size after it, and somewhere in there you started quietly choosing clothes that don't have a waistband at all. Dresses. Anything that ties. The jeans went to the back of the closet instead of the donation bag, because putting them in the bag would have meant admitting something.
You hadn't changed how you ate. If anything you were more careful than you'd been at thirty, because by then you'd been careful for a decade. And everyone you asked said the same thing. Metabolism slows down. It's perimenopause. This is what happens to women.
So you stopped asking. Not in a single dramatic moment — you just filed it under aging, the way you file anything that has stopped being a question.
When researchers interviewed twenty-nine peri- and postmenopausal women with PCOS in 2025, most described exactly this — sixty-nine percent reported weight gain that worsened with age, and about a third had arrived somewhere past hoping. One put it in a sentence: You have to just accept that it will never be better.
If you've thought some version of that, you're not being dramatic and you're not being weak. You're being reasonable with the information you were given.
The information was incomplete.
What the pattern was telling you
Here is what nobody said at any of those appointments.
Where your body puts weight is information. Not about your discipline. About your endocrinology.
Weight that arrives everywhere at once — arms, legs, face, middle — is a different physiological event from weight that goes almost entirely to your abdomen while your limbs stay exactly as they were. The first is a story about calories. The second is a story about hormones, and it is specific enough to be measured on a blood test.
You noticed this pattern years ago. You just weren't told it meant anything, so you read it as vanity instead of as the most useful clue in the picture.
It also isn't permanent. Hold onto that through the next part, because the mechanism is what earns it.
Why the fat went there and not somewhere else
Insulin resistance means your cells respond sluggishly to insulin, so your pancreas compensates by making more of it. That chronically elevated insulin does two things at once: it signals the theca cells in your ovaries to produce more androgens, and it suppresses your liver's production of SHBG, the protein that binds testosterone and keeps it inactive. More testosterone made, less of it bound. Free testosterone rises.
Androgens don't just affect skin and hair. They change the address fat is delivered to.
A study at UCLA funded by the NIH looked at normal-weight women with PCOS and found they stored fat differently — more fat packed around the internal organs of the abdomen, and less subcutaneous fat beneath the skin of the abdomen, buttocks and thighs, compared with women of the same weight without PCOS. The women in the study whose androgen levels were normal didn't show the abdominal pattern at all.
Read that again with your own closet in mind. Your arms and legs didn't stay the same because you got lucky above the waist. They stayed the same because the fat was being routed past them.
And the destination matters more than the size of the jeans. Subcutaneous fat — hips, thighs, the fat you can pinch — is relatively quiet storage. Visceral fat, the fat around your organs, drains straight into the portal vein and empties into your liver, delivering a constant supply of free fatty acids and inflammatory signals. The liver responds by producing more glucose and becoming less sensitive to insulin, regardless of your BMI. Higher insulin then drives more visceral storage.
It's a loop, and it tightens on itself. The belly isn't the result of the problem. It's participating in it.
Which is why this is a health question and not a clothing question. Women with PCOS carry roughly four times the odds of type 2 diabetes as women without it. In a meta-analysis of more than a million women, PCOS was associated with elevated odds of ischemic heart disease, and the 2023 international guideline now recommends cardiovascular risk assessment in PCOS regardless of age or BMI. A rising A1c is not a number about your size. It's your pancreas filing a report.
Willpower does not change a signal. Every behavior you can control sits downstream of the hormone. You can do everything correctly and barely move the outcome, because the instruction your body is receiving never changed. The effort wasn't failing. It was working, into a headwind nobody told you was there.
The part where perimenopause is also true
I'm not going to tell you your doctor invented the perimenopause explanation. It's real, and it does this.
As estrogen declines, fat genuinely redistributes from the hips and thighs toward the abdomen, and that shift happens independently of chronological aging. Across the transition, visceral fat climbs from roughly five to eight percent of total body fat to fifteen or twenty percent.
So the person who told you it was perimenopause wasn't wrong. They stopped one sentence too early.
Two processes are pushing in the same direction, in the same place, at the same time in your life. That's a reason to look harder, not a reason to stop looking — and it's exactly why this gets missed. The explanation that requires nothing of anyone happens to be partly true.
What to ask for
Ask for numbers before you ask for a prescription. A HbA1c or, better, an oral glucose tolerance test — the 2023 guideline names the OGTT first choice and A1c as less accurate but reasonable. A lipid panel. Blood pressure. Thyroid function too, and if the central pattern came on fast, ask what else is being ruled out, including Cushing's, and whether a medication you take could be contributing.
Then the two drugs worth asking about by name.
Metformin lowers the glucose your liver produces and improves how your tissues respond to insulin, and the international guideline recommends it for metabolic features in PCOS. It isn't FDA-approved for PCOS specifically — it's approved for type 2 diabetes and used off-label here, which is legal, decades old, and guideline-backed rather than fringe. The honest cost: GI upset for a lot of women, especially early and especially on the immediate-release form; extended-release is often tolerated better; long-term use warrants B12 monitoring.
GLP-1 receptor agonists slow gastric emptying, act on appetite signaling, and improve insulin sensitivity. Here the evidence needs care. Pooled trials in PCOS show modest short-term weight reduction and improved insulin resistance, but meta-analysis has not shown a significant effect on total testosterone, and the reproductive data stay thin. Real trade-offs: nausea and constipation, insurance fights and cash prices, muscle loss without enough protein and resistance training, and regain for many people who stop. They aren't for use in pregnancy and need a washout before trying to conceive.
Bring the sentence with you:
My weight gain has been almost entirely in my middle — my arms and legs haven't changed. That pattern makes me think insulin resistance. Can we check a HbA1c or a glucose tolerance test and a lipid panel, and talk about whether metformin or a GLP-1 makes sense for me?
Give it months, not weeks. And notice what actually improves, because it usually isn't the scale first — it's the A1c, the triglycerides, the afternoon crash, the cycle. Those are the wins.
Two doors, and then it's yours
The first door is your PCP, OB-GYN, or endocrinologist. Go, bring the sentence, ask for the labs in writing.
Know before you go that this gets missed constantly. PCOS affects roughly one in ten women and is still routinely handled with a birth control prescription and no metabolic workup at all. In that 2025 study, one woman had been through two endocrinologists, an OB-GYN and her family doctor, and said plainly that nobody was listening. If your appointment goes that way, you have learned something about that clinician's training, not about whether your symptoms are real. Ask for the labs anyway, or ask someone else.
The second door is telehealth built for this. Allara Health is a virtual practice for PCOS and women's hormonal and metabolic health that pairs clinicians with registered dietitians and works with many major insurance plans, though availability varies by state. Sesame is a direct-pay marketplace where you book a named clinician at a listed cash price without insurance or a referral — useful if you're uninsured, between plans, or facing a six-month wait for an endocrinologist.
I want to be clear that I have no financial relationship with either of these. I'm not an affiliate and I don't get paid if you book. I mention them because "find a doctor who actually knows PCOS" is useless advice without somewhere to start.
PCOS is managed, not cured, and I'm not going to promise you a number or a timeline. But the thing you were told to accept as your forties is a measurable signal with treatments that move it, and women with your exact labs have moved them. You were never required to make peace with this. You were only ever required to get it looked at.
The jeans can stay in the closet. That was never the point.
This is my experience and my reading of the research, not medical advice. Nothing here should replace a conversation with a clinician who knows your history.
Sources
- I feel like it gets worse as I get older: perspectives of peri-postmenopausal women with PCOS — Wright, Corbett, Dawson & Burts, Frontiers in Global Women's Health, 2025
- Fat-cell storage altered in women with infertility disorder — NICHD/NIH, on Dumesic et al., Journal of Clinical Endocrinology and Metabolism, 2016
- The pathophysiology of visceral adipose tissues in cardiometabolic diseases — Biochemical Pharmacology, 2024
- Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS — Teede et al., Journal of Clinical Endocrinology and Metabolism, 2023
- 2023 International Evidence-Based PCOS Guideline Update: meta-analysis on elevated clinical cardiovascular disease in PCOS — Journal of the American Heart Association, 2024
- Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in PCOS — Legro et al., Journal of Clinical Endocrinology and Metabolism, 1999
- The impact of the menopausal transition on body composition and abdominal fat redistribution — 2025
- GLP-1 receptor agonist treatment in women with polycystic ovary syndrome: a systematic review and meta-analysis — European Journal of Endocrinology, 2026